Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lansoprazole, quantity: 30 mg - capsule - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; indigo carmine; colloidal anhydrous silica; titanium dioxide; maize starch; purified talc; macrogol 300; sucrose; carmoisine; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - adults:. lanzopran capsules are indicated for. - healing and long-term management of reflux oesophagitis. . - healing and long-term management for patients with duodenal ulcer.. - healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . - patients with benign peptic lesions that do not respond to h2-receptor antagonists.. - eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics. . - relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric and adolescent patients i to 17 years of age:. lanzopran capsules are indicated for. - treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . - healing of erosive oesopha

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - lansoprazole -

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - lansoprazole 15mg - modified release capsule - 15 mg - active: lansoprazole 15mg excipient: allura red ac colloidal silicon dioxide fast green fcf gelatin heavy magnesium carbonate hyprolose     methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30% macrogol 6000 maize starch   polysorbate 80 purified talc   sucrose   sugar spheres tekprint black sw-9009 titanium dioxide   - healing and long-term management of reflux oesophagitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - lansoprazole 30mg - modified release capsule - 30 mg - active: lansoprazole 30mg excipient: brilliant blue fcf colloidal silicon dioxide erythrosine gelatin heavy magnesium carbonate hyprolose     methacrylic acid - ethyl acrylate copolymer (1:1) dispersion 30% macrogol 6000 maize starch   polysorbate 80 purified talc   sucrose   sugar spheres tekprint black sw-9009 titanium dioxide   - healing and long-term management of reflux oesophagitis.

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - lansoprazole - gastro-resistant capsule, hard - 30 milligram(s) - proton pump inhibitors; lansoprazole

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - lansoprazole - gastro-resistant capsule, hard - 15 milligram(s) - proton pump inhibitors; lansoprazole

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

dr. reddy`s laboratories malaysia sdn. bhd. - enzalutamide -

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lansoprazole, quantity: 30 mg - capsule - excipient ingredients: colloidal anhydrous silica; macrogol 300; gelatin; indigo carmine; carmoisine; maize starch; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; hypromellose; sucrose; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - adults:. lanzopran capsules are indicated for. - healing and long-term management of reflux oesophagitis. . - healing and long-term management for patients with duodenal ulcer.. - healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . - patients with benign peptic lesions that do not respond to h2-receptor antagonists.. - eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics. . - relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric and adolescent patients i to 17 years of age:. lanzopran capsules are indicated for. - treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . - healing of erosive oesopha

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lansoprazole, quantity: 15 mg - capsule - excipient ingredients: macrogol 300; iron oxide yellow; hypromellose; purified talc; maize starch; sucrose; titanium dioxide; methacrylic acid - ethyl acrylate copolymer (1:1); colloidal anhydrous silica; quinoline yellow; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - adults:. lanzopran capsules are indicated for. - healing and long-term management of reflux oesophagitis. . - healing and long-term management for patients with duodenal ulcer.. - healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . - patients with benign peptic lesions that do not respond to h2-receptor antagonists.. - eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics. . - relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric and adolescent patients i to 17 years of age:. lanzopran capsules are indicated for. - treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . - healing of erosive oesopha

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - lansoprazole, quantity: 15 mg - capsule - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); iron oxide yellow; sucrose; colloidal anhydrous silica; macrogol 300; titanium dioxide; gelatin; purified talc; maize starch; quinoline yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - adults:. lanzopran capsules are indicated for. - healing and long-term management of reflux oesophagitis. . - healing and long-term management for patients with duodenal ulcer.. - healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. . - patients with benign peptic lesions that do not respond to h2-receptor antagonists.. - eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics. . - relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. . paediatric and adolescent patients i to 17 years of age:. lanzopran capsules are indicated for. - treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. . - healing of erosive oesopha